Foghorn Therapeutics Inc.
For the period ended Apr 28, 2025. Filed Apr 28, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Apr 28, 2025 · Filed Apr 28, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · Selective CBP Degrader Program
Selective CBP Degrader Program
Poster Presentation Title: Establishing Rational Combination Strategies with Selective CBP Degraders in Solid Tumor Indications
Selective CBP degraders have combinatorial benefit with approved chemotherapies and targeted agents in solid tumors beyond EP300-mutant cancers. CBP and EP300 are highly similar acetyltransferases that share a bi-directional synthetic lethal relationship but are challenging to drug independently, and dual inhibition is associated with dose-limiting toxicities. Previously, we showed our selective CBP degraders have potent antiproliferative activity in EP300-mutant cancers.
Synergistic combination activity demonstrated, including with paclitaxel and CDK4/6 inhibitor abemaciclib in ER+ breast cancer
Findings support combination opportunities for selective CBP degraders in solid tumors beyond EP300-mutant cancers
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.